Transforming cancer treatment through empowered science

Seattle Genetics was founded in 1998, and since 2001 the company’s stock has been publicly traded on Nasdaq under the symbol SGEN. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer, has resulted in one approved drug and a robust pipeline of programs in clinical development for lymphoma, leukemia, urothelial (bladder) and breast cancer.

Recent News

  • Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer MORE
  • Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer MORE
  • Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer MORE

VIEW ALL NEWS

$63.86

 0.15 (0.23%)

10/20/17  4:00 p.m. ET

NASDAQ | SGEN (Common Stock)

High$65.15
Volume1,537,396
Low$63.30
Mkt Cap$9,133,717,631

Data provided by Nasdaq. Minimum 15 minutes delay

Seattle Genetics Fast Facts

NASDAQSGEN

Common Stock CUSIP812578 102

Fiscal Year Jan. 1 - Dec. 31

State IncorporatedDelaware

Transfer Agent Computershare

STAY CONNECTED

Investor Contact

Peggy Pinkston
Vice President, Investor Relations
investors@seagen.com
425-527-4160

Email Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Get email alerts